James E Manning1, Rachel M Anderson1, Anita Hill2, Doaa Zeidan3, Etienne Ciantar3. 1. School of Medicine, University of Leeds, Leeds, UK. 2. Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 3. Department of Obstetrics & Gynaecology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Abstract
Aims: To report pregnancy outcomes and complications in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria. Methods: A service evaluation of routinely collected medical records across 49 pregnancies in 21 women. Results: Eculizumab was used in 37 pregnancies, 31 of which (83.8%) ended in live birth. Eight infants (25.8%) were born prematurely. Over half (54%) of women required increases in their dose of eculizumab to control their haemolysis. There were no reported cases of maternal thrombosis. Major ante/postpartum bleeding necessitating urgent intervention was reported in 10.8% of pregnancies. There were two cases of intrauterine death and three miscarriages. There were no maternal or neonatal deaths. Three newborns required prolonged hospital stays. Conclusions: Eculizumab appears to benefit pregnant women with paroxysmal nocturnal haemoglobinuria and pregnancy outcomes following its use are largely good.
Aims: To report pregnancy outcomes and complications in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria. Methods: A service evaluation of routinely collected medical records across 49 pregnancies in 21 women. Results: Eculizumab was used in 37 pregnancies, 31 of which (83.8%) ended in live birth. Eight infants (25.8%) were born prematurely. Over half (54%) of women required increases in their dose of eculizumab to control their haemolysis. There were no reported cases of maternal thrombosis. Major ante/postpartum bleeding necessitating urgent intervention was reported in 10.8% of pregnancies. There were two cases of intrauterine death and three miscarriages. There were no maternal or neonatal deaths. Three newborns required prolonged hospital stays. Conclusions: Eculizumab appears to benefit pregnant women with paroxysmal nocturnal haemoglobinuria and pregnancy outcomes following its use are largely good.
Authors: Richard J Kelly; Britta Höchsmann; Jeff Szer; Austin Kulasekararaj; Sophie de Guibert; Alexander Röth; Ilene C Weitz; Elina Armstrong; Antonio M Risitano; Christopher J Patriquin; Louis Terriou; Petra Muus; Anita Hill; Michelle P Turner; Hubert Schrezenmeier; Regis Peffault de Latour Journal: N Engl J Med Date: 2015-09-10 Impact factor: 91.245
Authors: Russell P Rother; Scott A Rollins; Christopher F Mojcik; Robert A Brodsky; Leonard Bell Journal: Nat Biotechnol Date: 2007-11 Impact factor: 54.908
Authors: Peter Hillmen; Petra Muus; Ulrich Dührsen; Antonio M Risitano; Jörg Schubert; Lucio Luzzatto; Hubert Schrezenmeier; Jeffrey Szer; Robert A Brodsky; Anita Hill; Gerard Socié; Monica Bessler; Scott A Rollins; Leonard Bell; Russell P Rother; Neal S Young Journal: Blood Date: 2007-08-16 Impact factor: 22.113